Beam reports early gene editing data; Pfizer partners with Enodia
Beam Therapeutics released initial Phase 1/2 results for a base editing therapy targeting glycogen storage disease type Ia. The data suggest the treatment can correct the underlying mutation. Separately, Pfizer will collaborate with Enodia.
Expanded Detail
EXPANDED:
Beam Therapeutics has shared first clinical-stage findings for an experimental base editor aimed at glycogen storage disease type Ia. According to the company, the early Phase 1/2 data hint that the approach may fix the mutation responsible for the condition. In a separate move, Pfizer plans to work with Enodia. Together, these items reflect two common features of modern drug development: gene-editing candidates entering initial human testing and companies forming external research alliances
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
CRISPR Therapeutics to Share Phase 1b Data for CTX310 at AHA 2026 · Drug development
NTX-253 Moves Toward Phase 2 Testing for Schizophrenia · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Beam suggests it can correct mutation; Pfizer to collaborate with Enodia.” Browse more stories.